Tricyclic benzazepine vasopressin antagonists

A compound selected from Formula I:

• ##STR140## wherein;
• A--B is ##STR141## R.sub.1 is H, halogen (chlorine, fluorine, bromine, iodine), OH, --S-lower alkyl (C.sub.1 -C.sub.3), --SH, --SO lower alkyl (C.sub.1 -C.sub.3), --SO.sub.2 lower alkyl (C.sub.1 -C.sub.3), --CO lower alkyl (C.sub.1 -C.sub.3), --CF.sub.3, lower alkyl (C.sub.1 -C.sub.3), --O lower alkyl (C.sub.1 -C.sub.3), --NO.sub.2, --NH.sub.2, --NHCO lower alkyl (C.sub.1 -C.sub.3), --N-- lower alkyl (C.sub.1 -C.sub.3)!.sub.2, SO.sub.2 NH.sub.2, --SO.sub.2 NH lower alkyl (C.sub.1 -C.sub.3), or --SO.sub.2 N lower alkyl (C.sub.1 -C.sub.3)!.sub.2 ;
• R.sub.2 is H, CI, Br, I, F, --OH, lower alkyl (C.sub.1 -C.sub.3), --O lower alkyl (C.sub.1 -C.sub.3);
• or
• R.sub.1 and R.sub.2 taken together are methylenedioxy or ethylenedioxy;
• R.sub.3 is the moiety ##STR142## wherein Ar is a moiety selected from the group ##STR143## and X is selected from O, S, --NCH.sub.3, or --N--COCH.sub.3 ;
• R.sub.4 is selected from H, lower alkyl (C.sub.1 -C.sub.3), --CO-lower alkyl (C.sub.1 -C.sub.3), SO.sub.2 lower alkyl (C.sub.1 -C.sub.3), and the moieties of the formulae:
• ##STR144## R.sub.5 is H, --CH.sub.3, --C.sub.2 H.sub.5, Cl, Br, F, --O--CH.sub.3, or --O--C.sub.2 H.sub.5 ;
• R.sub.6 is selected from:
• (a) moieties of the formula:
• ##STR145## wherein cycloalkyl is defined as C.sub.3 -C.sub.6 cycloalkyl, cyclohexenyl or cyclopentenyl;
• R.sub.2 is as hereinbefore defined;
• n is 0-2;
• R.sub.7 is H, --CH.sub.3, --C.sub.2 H.sub.5, Cl, Br, F, --OCH.sub.3, --OC.sub.2 H.sub.5, or --CF.sub.3 ;
• R.sub.a is hydrogen, CH.sub.3, C.sub.2 H.sub.5, moieties of the formulae:
• ##STR146## --(CH.sub.2).sub.2 --O-lower alkyl (C.sub.1 -C.sub.3) or --CH.sub.2 CH.sub.2 OH;
• q is one or two;
• R.sub.b is hydrogen, --CH.sub.3 or --C.sub.2 H.sub.5 ;
• Ar' is selected from the group:
• ##STR147## wherein R.sub.4, R.sub.5 are as hereinbefore defined;
• R.sub.8 and R.sub.9 are independently hydrogen, lower alkyl (C.sub.1 -C.sub.3), O-lower alkyl (C.sub.1 -C.sub.3), S-lower alkyl (C.sub.1 -C.sub.3), --CF.sub.3, --CN, --OH, --SCF.sub.3, --OCF.sub.3, halogen, NO.sub.2, amino, or --NH-lower alkyl (C.sub.1 -C.sub.3);
• R.sub.10 is selected from halogen, hydrogen, or lower alkyl (C.sub.1 -C.sub.3);
• W' is selected from O, S, NH, N-lower alkyl (C.sub.1 -C.sub.3), --NCO-lower alkyl (C.sub.1 -C.sub.3), or NSO.sub.2 -lower alkyl (C.sub.1 -C.sub.3);
• and
• (b) a moiety of the formula:
• ##STR148## where R.sub.2 is as hereinbefore defined;
• (c) a moiety of the formula:
• ##STR149## wherein J is R.sub.a, lower alkyl (C.sub.1 -C.sub.8) branched or unbranched, lower alkenyl (C.sub.2 -C.sub.8) branched or unbranched, --O-lower alkyl (C.sub.1 -C.sub.8) branched or unbranched, --O-lower alkenyl (C.sub.2 -C.sub.8) branched or unbranched, tetrahydrofuran, tetrahydrothiophene, or --CH.sub.2 --K wherein K is halogen, --OH, tetrahydrofuran, tetrahydrothiophene or the heterocyclic ring moiety:
• ##STR150## wherein D, E, F and G are selected from carbon or nitrogen and wherein the carbon atoms may be optionally substituted with halogen, (C.sub.1 -C.sub.3)lower alkyl, hydroxy, --CO-lower alkyl (C.sub.1 -C.sub.3), CHO, (C.sub.1 -C.sub.3)lower alkoxy, or --CO.sub.2 -lower alkyl (C.sub.1 -C.sub.3), and R.sub.a and R.sub.b are as hereinbefore defined;
• (d) a moiety selected from those of the formulae:
• ##STR151## wherein R.sub.c is selected from halogen, (C.sub.1 -C.sub.3) lower alkyl, --O-lower alkyl (C.sub.1 -C.sub.3) or OH;
• R.sub.b is as hereinbefore defined;
• q is 1 or 2;
• wherein Ar' is selected from the group:
• ##STR152## R.sub.8 and R.sub.9 are independently hydrogen, lower alkyl (C.sub.1 -C.sub.3), O-lower alkyl (C.sub.1 -C.sub.3), S-lower alkyl (C.sub.1 -C.sub.3), --CF.sub.3, --CN, --OH, --SCF.sub.3, --OCF.sub.3, halogen, NO.sub.2, amino, or --NH-lower alkyl (C.sub.1 -C.sub.3);
• R.sub.10 is selected from the group of halogen, hydrogen, or lower alkyl (C.sub.1 -C.sub.3);
• W' is selected from O, S, NH, N-lower alkyl (C.sub.1 -C.sub.3), --NCO-lower alkyl (C.sub.1 -C.sub.3), or NSO.sub.2 -lower alkyl (C.sub.1 -C.sub.3);
• or a pharmaceutically acceptable salt, ester or prodrug thereof.